Thomas Secher (Thomas Sécher)

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 4

Top Topics

Chronic Obstructive Pulmonary Disease

Pseudomonas Aeruginosa

Small Cell Lung Cancer

Electronic Health Record

Top Venues

Antibodies (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Secher, Elsa Bodier-Montagutelli, Christelle Parent, Laura Bouvart, Mélanie Cortes, Marion Ferreira, Ronan MacLoughlin, Guy Ilango, Otmar Schmid, Renaud Respaud, Nathalie Heuzé-Vourc'h
Aggregates Associated with Instability of Antibodies during Aerosolization Induce Adverse Immunological Effects. Pharmaceutics 14 (3) (2022)
Aubin Pitiot, Nathalie Heuzé-Vourc'h, Thomas Secher
Alternative Routes of Administration for Therapeutic Antibodies-State of the Art. Antibodies (Basel, Switzerland) 11 (3) (2022)
Marion Ferreira, Thomas Secher, Nathalie Heuze-Vourc'H, Karen L Reckamp
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. Pharmaceutics 13 (6) (2021)
Claire Mackowiak, Tiffany Marchiol, Hana Cipcic Paljetak, Louis Fauconnier, Jennifer Palomo, Thomas Secher, Corinne Panek, Delphine Sedda, Florence Savigny, Francois Erard, Alessandra Bragonzi, François Huaux, Tobias Stoeger, Herbert B Schiller, Jean-Claude Sirard, Marc Le Bert, Isabelle Couillin, Valerie F J Quesniaux, Dieudonnée Togbe, Bernhard Ryffel
Chronic Pseudomonas aeruginosa Lung Infection Is IL-1R Independent, but Relies on MyD88 Signaling. ImmunoHorizons 5 (5) (2021)